🔄 Cyclic Peptide Technology¶
Cyclic peptides are formed by chemically cyclizing the N-terminus and C-terminus (or side chains) of linear peptides, conferring conformational rigidity, proteolytic stability, and receptor binding selectivity. Cyclization is one of the most effective modification strategies in peptide drug development.
1. Core Advantages of Cyclic Peptides¶
| Advantage Dimension | Linear Peptides | Cyclic Peptides | Improvement |
|---|---|---|---|
| Metabolic Stability (Plasma Half-Life) | t₁/₂ < 30 min | t₁/₂ 2–24 h | ↑ 5–50× |
| Conformational Freedom | High (random coil) | Low (rigid structure) | ↓ Conformational entropy |
| Receptor Binding Affinity | nM–μM | pM–nM | ↑ 10–1000× |
| Oral Potential | Very low | Moderate (Cyclosporine: 30% BA) | Significantly improved |
| Cell Membrane Permeability | Very low | Some cyclic peptides can penetrate | Case-specific |
| Selectivity | Moderate | High | ↑ Reduced off-target effects |
Physicochemical Properties of Cyclic Peptides
Cyclization reduces the molecule's polar surface area, restricts flexibility, and pre-organizes the conformational backbone — changes that collectively enhance binding affinity to target proteins. The well-known cyclosporine A (Cyclosporine A, an 11 aa cyclic peptide) is a successful example of an oral cyclic peptide, with oral bioavailability reaching 30%, far exceeding the vast majority of linear peptides.
2. Cyclic Peptide Synthesis Methods¶
2.1 Synthesis Strategy Comparison¶
| Cyclization Method | Connection Sites | Experimental Difficulty | Yield | Suitable Scenarios |
|---|---|---|---|---|
| Head-to-Tail Cyclization | N-term ↔ C-term | Medium | 30–70% | General cyclic peptides |
| Side Chain-to-Side Chain Cyclization | Side chain groups (Lys/Asp etc.) | Medium–High | 20–50% | Bridged cyclic peptides |
| Head-to-Side Chain Cyclization | N-term ↔ Side chain (Lys side chain) | Medium | 30–60% | Selective cyclization |
| Side Chain-to-Tail Cyclization | Side chain ↔ C-term | Medium | 25–55% | Protected side chain cyclization |
| Disulfide Bond Cyclization | Cys–Cys disulfide bond | Low | 40–80% | Natural peptide mimicry |
| Click Chemistry Cyclization | Azide-alkyne (CuAAC/SPAAC) | Medium | 50–90% | Orthogonal synthesis |
2.2 Industrial Methods¶
| Method | Equipment Requirements | Achievable Scale | Purity | Cost |
|---|---|---|---|---|
| On-Resin Cyclization | Standard SPPS synthesizer | mg–10 g | Medium | Medium |
| Liquid-Phase Dilution Cyclization | Reaction vessel | 10 g–kg | High | Mid–High |
| Pseudo-Dilution Continuous Flow | Continuous flow reactor | kg scale | Very High | High |
| Enzymatic Cyclization | Enzyme reactor | mg–g | Very High | High |
Industrial Scale-Up Challenge
Liquid-phase cyclization requires high dilution (typically <1 mM) to avoid intermolecular polymerization, which limits scale economics. Continuous flow reactors, through precise control of mixing and reaction time, can achieve high-concentration cyclization at 10–50 mM, making them the ideal solution for industrialization.
3. Key Marketed Cyclic Peptide Drugs¶
| Drug (Brand Name) | Amino Acid Count | Cyclization Type | Indication | Company | 2024 Sales |
|---|---|---|---|---|---|
| Cyclosporine A (Neoral®) | 11 aa | Head-to-tail cyclization | Immunosuppression | Novartis | ~$1.5B |
| Octreotide (Sandostatin®) | 8 aa | Disulfide + cyclic | Acromegaly / NET | Novartis | ~$1.2B |
| Lanreotide (Somatuline®) | 8 aa | Disulfide + cyclic | Acromegaly / NET | Ipsen | ~$1.0B |
| Carfilzomib (Kyprolis®) | 4 aa | Epoxyketone cyclization | Multiple myeloma | Amgen | ~$1.3B |
| Tezacaftor | Modified peptide | Multiple cyclization | Cystic fibrosis | Vertex | ~$1.2B |
| Vancomycin | Cyclic glycopeptide | Multi-cross cyclization | Bacterial infection | Multiple | ~$1.5B |
| Polymyxin B/E | Cyclic lipopeptide | Cyclization | Drug-resistant infection | Multiple | ~$0.5B |
| Daptomycin | 13 aa cyclic lipopeptide | Cyclization | Drug-resistant infection | Merck | ~$1.0B |
| Linaclotide (Linzess) | 14 aa | Disulfide cyclization | IBS-C / CIC | AbbVie | ~$1.0B+ |
| Plecanatide (Trulance) | 16 aa | Disulfide cyclization | CIC | Bausch | ~$0.3B |
| Bicycle® Candidates | 10–15 aa | Bicyclization | Oncology / Inflammation | Bicycle Tx | Clinical stage |
Cyclic Peptide Drug Share
As of 2025, of the approximately 80 marketed peptide drugs globally, about 30 (38%) contain cyclic structures, contributing ~50% of total peptide market revenue. The average annual sales of cyclic peptide drugs are approximately 2.5× that of linear peptide drugs.
4. Therapeutic Application Areas¶
| Therapeutic Area | Representative Cyclic Peptide | Mechanism | Phase |
|---|---|---|---|
| Immunosuppression | Cyclosporine A | Calcineurin inhibition | ✅ Marketed |
| Oncology | Carfilzomib, PDC cyclic peptide carriers | Proteasome inhibition / Targeted delivery | ✅ Marketed + Clinical |
| Anti-Infective | Vancomycin, Daptomycin | Cell wall synthesis inhibition / Membrane disruption | ✅ Marketed |
| Endocrine | Octreotide, Lanreotide | Somatostatin receptor agonism | ✅ Marketed |
| Gastrointestinal | Linaclotide, Plecanatide | GC-C receptor agonism | ✅ Marketed |
| Metabolic Disease | Novel GLP-1 cyclic peptides (in R&D) | GLP-1 receptor agonism | 🔬 Phase I–II |
| Anti-Inflammatory / Autoimmune | α-MSH cyclic peptide mimetics | MC1R agonism | 🔬 Phase II |
| Pain Management | κ-opioid receptor cyclic peptides | κ-opioid receptor agonism | 🔬 Phase II |
| Rare Diseases | Various cyclic peptide targeted therapies | Protein-protein interaction inhibition | 🔬 Phase I–II |
5. R&D Frontiers¶
| Frontier Direction | Technical Focus | Representative Platform/Company |
|---|---|---|
| Bicyclic Peptides (Bicycles®) | Synthetic cyclic peptide libraries with dual ring cores, high affinity + high selectivity | Bicycle Therapeutics, ~$5B valuation |
| Cyclic Peptide-Drug Conjugates | Cyclic peptides as targeting carriers conjugated to cytotoxic drugs | Bicycle, Multiple |
| Oral Cyclic Peptide Design | N-methylation + side chain modification to improve oral bioavailability | Cyclosporine modification / novel design |
| Cyclic Peptide Phage Display | Construction of large cyclic peptide libraries for hit and lead screening | Dyax (Shire/Takeda) |
| mRNA Display Cyclic Peptide Libraries | In vitro ultra-high-throughput screening | Ra Pharmaceuticals (UCB) |
| AI/ML-Assisted Cyclic Peptide Design | Prediction of cyclization propensity, conformational stability, and ADME | Multiple teams |
🔬 Cyclic Peptide CDMO Services: SENO Biotechnology provides complete capabilities from mg-scale cyclic peptide process development to kg-scale GMP commercial production, covering head-to-tail cyclization, disulfide cyclization, side chain cyclization, and click chemistry cyclization methods. SENO Biotechnology — Your Peptide R&D and Production Partner, visit senopeptide.com/platforms/ for details on cyclic peptide synthesis services.